<prof_article_slide_presentation><front_label>Front Matter</front_label><above_title/><title><p>Diagnostic and Management Challenges in Patients With Chronic Migraine</p></title><contrbtr_pre_content><p>As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest.  The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.</p><p>Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.</p></contrbtr_pre_content><contrbtr_byline><p>Richard Lipton, MD; Dawn C. Buse, PhD; David Dodick, MD; Rashmi B. Halker Singh, MD</p></contrbtr_byline><contrbtr_bulk_info/><contrbtr_post_content><h3>Peer Reviewer</h3><p>This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.</p></contrbtr_post_content><supprtr_grant_group/><body_label>Body</body_label><toc_element><toc_label/><toc_type>Default</toc_type><sec_element><sec_header/><subsec_element><subsec_header><p>Contents of This CME Activity</p></subsec_header><slide_intro><style type="text/css">
        div.articleTitle {
            font-size: 1.2em;
            font-weight: bold;
        }

        div#prgteaser {
            clear: left;
            padding-top: 10px;
        }
    </style><p>All sections of this activity are required for credit.</p><div id="prgteaser"><img src="professional_assets/medscape/images/thumbnail_library/900319_2.jpg?interpolation=lanczos-none&resize=200:150" alt=""/><h4> Diagnostic and Management Challenges in Patients With Chronic Migraine</h4>  Dr Lipton introduces this program on the management of patients with migraine.<br/><em> Richard Lipton, MD</em></div><div id="prgteaser"><img src="professional_assets/medscape/images/thumbnail_library/900319_3.jpg?interpolation=lanczos-none&resize=200:150" alt=""/><h4> Stigma and Quality of Life in Patients With Frequent Migraine</h4>  Dr Buse reviews data from the CaMEO study showing the effects of frequent migraine on patients and their families.<br/><em> Dawn Buse, PhD</em></div><div id="prgteaser"><img src="professional_assets/medscape/images/thumbnail_library/900319_4.jpg?interpolation=lanczos-none&resize=200:150" alt=""/><h4> Considerations in Preventive Therapy for Migraine</h4>  Dr Lipton discusses key issues facing clinicians when considering preventive treatment for patients with migraine.<br/><em> Richard Lipton, MD</em></div><div id="prgteaser"><img src="professional_assets/medscape/images/thumbnail_library/900319_5.jpg?interpolation=lanczos-none&resize=200:150" alt=""/><h4> Migraine Headache: A Treatment Update</h4>  Dr Dodick discusses the role of new and emerging options for the prevention and treatment of migraine.<br/><em> David Dodick, MD</em></div><div id="prgteaser"><img src="professional_assets/medscape/images/thumbnail_library/900319_6.jpg?interpolation=lanczos-none&resize=200:150" alt=""/><h4> Emerging Approaches for Preventive Therapy of Chronic Migraine</h4>  Dr Halker Singh reviews the most recent data on CGRP-targeting monoclonal antibodies for the prevention of chronic migraine.<br/><em> Rashmi B. Halker Singh, MD</em></div><div class="spacer">&#160;</div></slide_intro></subsec_element></sec_element><sec_element><sec_header><p>Educational Impact Challenge</p></sec_header><subsec_element><subsec_header/><slide_intro><p>The goal of this activity is to review recent data on the need for improved treatment strategies for patients with chronic migraine, and the role that new and emerging monoclonal antibodies can play in preventing, treating, and minimizing the burden of migraine.</p><p>Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.</p></slide_intro><slide_grp><sec_img/><sec_label/><sec_caption/><sec_txt/><sec_alt_txt/><qna_form>3</qna_form></slide_grp></subsec_element></sec_element><pg_footnotes/></toc_element><toc_element><toc_label/><toc_type>Default</toc_type><sec_element><sec_header><p> Diagnostic and Management Challenges in Patients With Chronic Migraine</p></sec_header><subsec_element><subsec_header/><slide_intro><div class="app-loading"><div class="webcomp-player" data-config="en/pi/editorial/studio/configs/2019/education/900319/900319_2.json" data-playertype="edu" id="cme-video-player">
                &#160;
            </div></div></slide_intro><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_2/Slide1.png</sec_img><sec_label>Slide 1.</sec_label><sec_caption/><sec_txt><h3> Diagnostic and Management Challenges in Patients With Chronic Migraine</h3></sec_txt><sec_alt_txt>Slide 1.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_2/Slide2.png</sec_img><sec_label>Slide 2.</sec_label><sec_caption/><sec_txt><h3> Faculty</h3></sec_txt><sec_alt_txt>Slide 2.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_2/Slide3.png</sec_img><sec_label>Slide 3.</sec_label><sec_caption/><sec_txt><h3> Disclaimer</h3></sec_txt><sec_alt_txt>Slide 3.</sec_alt_txt><qna_form/></slide_grp></subsec_element></sec_element><pg_footnotes/></toc_element><toc_element><toc_label/><toc_type>Default</toc_type><sec_element><sec_header><p> Stigma and Quality of Life in Patients With Frequent Migraine</p></sec_header><subsec_element><subsec_header/><slide_intro><div class="app-loading"><div class="webcomp-player" data-config="en/pi/editorial/studio/configs/2019/education/900319/900319_3.json" data-playertype="edu" id="cme-video-player">
                &#160;
            </div></div></slide_intro><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_3/Slide1.png</sec_img><sec_label>Slide 1.</sec_label><sec_caption/><sec_txt><h3> Stigma and Quality of Life in Patients With Frequent Migraine</h3></sec_txt><sec_alt_txt>Slide 1.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_3/Slide2.png</sec_img><sec_label>Slide 2.</sec_label><sec_caption/><sec_txt><h3> CaMEO Study: Background<sup type="ref">[1]</sup></h3><ul><li>	Nearly 20,000 respondents invited to complete Family Burden Module
<ul><li>	Asked respondents to postulate how their lives would be different if they did not have migraine </li></ul></li></ul></sec_txt><sec_alt_txt>Slide 2.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_3/Slide3.png</sec_img><sec_label>Slide 3.</sec_label><sec_caption/><sec_txt><h3> CaMEO Study: Patient Demographics<sup type="ref">[2]</sup></h3></sec_txt><sec_alt_txt>Slide 3.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_3/Slide4.png</sec_img><sec_label>Slide 4.</sec_label><sec_caption/><sec_txt><h3> CaMEO Study: Effect of Migraine on Life if I Didn't Have Migraine<sup type="ref">[2]</sup></h3><ul><li>	Most patients with chronic migraine (CM) and episodic migraine (EM) indicated overall health, stress levels, and enjoyment of free time would be better or a lot better without migraine</li><li>	Across 9 domains assessed, almost 90% of respondents with CM and 70% with EM said lives would be better or a lot better in at least 1 area without migraine</li></ul></sec_txt><sec_alt_txt>Slide 4.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_3/Slide5.png</sec_img><sec_label>Slide 5.</sec_label><sec_caption/><sec_txt><h3> CaMEO Study: Effect of Migraine on Personal Career and Finances<sup type="ref">[3]</sup></h3><ul><li>	Second analysis focusing on the perceived impact of migraine on career and finances</li><li>	Increasing headache day frequency in EM and CM groups associated with higher rates of concern</li></ul></sec_txt><sec_alt_txt>Slide 5.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_3/Slide6.png</sec_img><sec_label>Slide 6.</sec_label><sec_caption/><sec_txt><h3> CaMEO Study: Effect of Migraine on Partner's Career and Finances<sup type="ref">[3]</sup></h3><ul><li>	Respondents reported spouse or partner career adversely affected career advancement
<ul><li>	Missed work, changing jobs, or leaving or passing up a job</li><li>	Those with CM twice as likely vs EM to agree somewhat or completely</li></ul></li></ul></sec_txt><sec_alt_txt>Slide 6.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_3/Slide7.png</sec_img><sec_label>Slide 7.</sec_label><sec_caption/><sec_txt><h3> CaMEO Study: Effect of Migraine on Relationships<sup type="ref">[4]</sup></h3><ul><li>	Third analysis examined perceived effect of migraine on family activities, relationships, emotional reactions, and major life decisions
<ul><li>	65% of respondents in an intimate relationship such as marriage or domestic partnership or were living together</li><li>	10% in a committed relationship but not living together</li><li>	About one-quarter not currently involved in an intimate relationship</li><li>	Subset of questions about parenting and effect on children for those with children living in the home</li></ul></li><li>	Approximately 20% of those not in a relationship or in a relationship and not living together indicated headaches contributed to relationship problems in the past</li><li>	Increasing headache day frequency was associated with increased rates of endorsement that migraine or headaches cause problems
<ul><li>	Held true for all areas of relationships </li></ul></li></ul></sec_txt><sec_alt_txt>Slide 7.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_3/Slide8.png</sec_img><sec_label>Slide 8.</sec_label><sec_caption/><sec_txt><h3> Conclusions</h3></sec_txt><sec_alt_txt>Slide 8.</sec_alt_txt><qna_form/></slide_grp></subsec_element></sec_element><pg_footnotes/></toc_element><toc_element><toc_label/><toc_type>Default</toc_type><sec_element><sec_header><p> Considerations in Preventive Therapy for Migraine</p></sec_header><subsec_element><subsec_header/><slide_intro><div class="app-loading"><div class="webcomp-player" data-config="en/pi/editorial/studio/configs/2019/education/900319/900319_4.json" data-playertype="edu" id="cme-video-player">
                &#160;
            </div></div></slide_intro><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_4/Slide1.png</sec_img><sec_label>Slide 1.</sec_label><sec_caption/><sec_txt><h3> Considerations in Preventive Therapy for Migraine</h3></sec_txt><sec_alt_txt>Slide 1.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_4/Slide2.png</sec_img><sec_label>Slide 2.</sec_label><sec_caption/><sec_txt><h3> Patterns of Preventive Therapy Use: IBMS-II<sup type="ref">[5]</sup></h3><ul><li>	After starting on oral generic preventive medications for migraine
<ul><li>	After 6 months, only 25% remain on treatment</li><li>	After a year, only 15% remain on treatment</li></ul></li><li>	If ask people why they discontinue, they give 2 major reasons independent of what class of medication they are on
<ul><li>	The medicine does not work well enough</li><li>	The medicine causes too many side effects</li></ul></li></ul></sec_txt><sec_alt_txt>Slide 2.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_4/Slide3.png</sec_img><sec_label>Slide 3.</sec_label><sec_caption/><sec_txt><h3> Weighing Treatment Efficacy and Tolerability</h3><ul><li>	When thinking about whether to continue a patient on preventive treatment, look at 2 × 2 table of efficacy vs side effects
<ul><li>	In cell A, the treatment is working, does not produce side effects</li><li>	Very likely the treatment that should be continued</li></ul></li><li>	In cell D, the treatment is not effective and produces side effects
<ul><li>	Very little chance patients will continue treatment and clinicians also unlikely to continue</li></ul></li><li>	Cell C is the most common situation with oral generic preventive medications for migraine
<ul><li>	Medication is at least somewhat effective but also producing side effects</li><li>	Patients and clinicians have a difficult choice to make</li></ul></li><li>	Emerging monoclonal antibodies (mAbs) for migraine are particularly attractive
<ul><li>	They provide efficacy with little in the way of penalty in terms of adverse events</li><li>	Much greater chance of keeping people in cell A</li></ul></li></ul></sec_txt><sec_alt_txt>Slide 3.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_4/Slide4.png</sec_img><sec_label>Slide 4.</sec_label><sec_caption/><sec_txt><h3> Measuring Migraine Burden in All Phases<sup type="ref">[6,7]</sup></h3><ul><li>	Phases of migraine
<ul><li>	In the preheadache (premonitory/prodrome) phase, people may have symptoms or auras</li><li>	In the postheadache (postdrome) phase, people may have changes in mood or behavior, fatigue, and scalp sensitivity</li></ul></li></ul></sec_txt><sec_alt_txt>Slide 4.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_4/Slide5.png</sec_img><sec_label>Slide 5.</sec_label><sec_caption/><sec_txt><h3> Measuring Burden of Migraine Before, During, and After Migraine: MPFID<sup type="ref">[8,9]</sup></h3><ul><li>	New study data on measuring the burden of migraine during the headache phase, and on the day before and the day after headache</li><li>	Migraine Physical Function Impact Diary (MPFID) used to measure disability on headache days and nonheadache days
<ul><li>	Daily diary measure, asks 13 questions about ability to function</li></ul></li></ul></sec_txt><sec_alt_txt>Slide 5.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_4/Slide6.png</sec_img><sec_label>Slide 6.</sec_label><sec_caption/><sec_txt><h3> Burden on Everyday Activities and Physical Impairment by Migraine Phase<sup type="ref">[9]</sup></h3><ul><li>	MPFID shows burden on headache days is much greater than on days where no headache is present</li><li>	Substantial burden on prodromal and postdromal days
<ul><li>	Previously unappreciated in migraine studies</li></ul></li><li>	In future studies, measure the burden of migraine and treatment benefits on headache days, prodromal days, and postdromal days
<ul><li>	Get a fuller picture both of the burden of disease and the benefits of treatment</li></ul></li></ul></sec_txt><sec_alt_txt>Slide 6.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_4/Slide7.png</sec_img><sec_label>Slide 7.</sec_label><sec_caption/><sec_txt><h3> Identifying Natural Subgroups of Migraine<sup type="ref">[10]</sup></h3><ul><li>	Study identifying natural subgroups of migraine to address questions
<ul><li>	Why is migraine so common?</li><li>	Why do the clinical features of migraine vary so much from person to person?</li><li>	Why is treatment response so variable?
<ul><li>	Why does one person respond to a tricyclic antidepressant, another to a beta-blocker, and another to an antiepilepsy drug?</li></ul></li><li>	Why has it been so difficult to identify genes for migraine?
<ul><li>	Identified genes for rare forms of migraine like familial hemiplegic migraine</li></ul></li><li>	Most of genetic determinants of more common forms of migraine remain to be identified</li></ul></li><li>	Solution is to do a better job of characterizing natural subgroups of people with migraine
<ul><li>	One approach is to use comorbidity profiles
<ul><li>	Use conditions that travel along with migraine to identify natural subgroups of migraine</li></ul></li></ul></li></ul></sec_txt><sec_alt_txt>Slide 7.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_4/Slide8.png</sec_img><sec_label>Slide 8.</sec_label><sec_caption/><sec_txt><h3> Natural Subgroups of Migraine: Overall Results<sup type="ref">[10]</sup></h3><ul><li>	Examined people with migraine and 22 comorbidities
<ul><li>	Discovered 8 natural subgroups</li></ul></li></ul></sec_txt><sec_alt_txt>Slide 8.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_4/Slide9.png</sec_img><sec_label>Slide 9.</sec_label><sec_caption/><sec_txt><h3> Natural Subtype of Migraine: Likelihood of Progression to CM<sup type="ref">[10]</sup></h3><ul><li>	Subgroups differed widely in prognosis
<ul><li>	Group with the most comorbidities was most likely to progress to CM</li><li>	Group with the fewest comorbidities was least likely to progress</li><li>	Substantial differences among groups in prognosis</li></ul></li></ul></sec_txt><sec_alt_txt>Slide 9.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_4/Slide10.png</sec_img><sec_label>Slide 10.</sec_label><sec_caption/><sec_txt><h3> Looking Ahead</h3><ul><li>	Open questions
<ul><li>	Will these subgroups predict response to treatment?</li><li>	Will they correlate with neuroimaging abnormalities found in migraine?</li></ul></li><li>	Important clinical question
<ul><li>	Instead of engaging in a trial-and-error-process for treatment, might be able to get treatment right the first time</li></ul></li></ul></sec_txt><sec_alt_txt>Slide 10.</sec_alt_txt><qna_form/></slide_grp></subsec_element></sec_element><pg_footnotes/></toc_element><toc_element><toc_label/><toc_type>Default</toc_type><sec_element><sec_header><p> Migraine Headache: A Treatment Update</p></sec_header><subsec_element><subsec_header/><slide_intro><div class="app-loading"><div class="webcomp-player" data-config="en/pi/editorial/studio/configs/2019/education/900319/900319_5.json" data-playertype="edu" id="cme-video-player">
                &#160;
            </div></div></slide_intro><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_5/Slide1.png</sec_img><sec_label>Slide 1.</sec_label><sec_caption/><sec_txt><h3> Migraine Headache: A Treatment Update</h3></sec_txt><sec_alt_txt>Slide 1.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_5/Slide2.png</sec_img><sec_label>Slide 2.</sec_label><sec_caption/><sec_txt><h3> Lasmiditan for Acute Treatment of Migraine<sup type="ref">[11,12]</sup></h3><ul><li>	Two recent updates in acute treatment of migraine</li><li>	New 5-hydroxytryptamine (5-HT)<sub>1F</sub> receptor agonist lasmiditan
<ul><li>	Built on the platform of triptans, which are 5-HT<sub>1B, 1D</sub>, and to some extent, 5-HT<sub>1F</sub> receptor agonists</li><li>	Because of the 1D receptor agonism, triptans are contraindicated in patients with cardiovascular disease or significant risk factors for cardiovascular disease</li></ul></li><li>	Lasmiditan removed the 1B and the 1D agonism and just left the 1F receptor agonism
<ul><li>	1F receptors are not located on blood vessels, so there is no cardiovascular liability associated with this medication</li></ul></li><li>	Results of 2 large studies reported: SAMURAI and SPARTAN
<ul><li>	Both large, placebo-controlled, randomized, double-blind studies evaluating efficacy and safety of lasmiditan for acute treatment of migraine</li></ul></li></ul></sec_txt><sec_alt_txt>Slide 2.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_5/Slide3.png</sec_img><sec_label>Slide 3.</sec_label><sec_caption/><sec_txt><h3> Lasmiditan: Phase 3 Study Results<sup type="ref">[12]</sup></h3><ul><li>	Used by patients to treat moderate or severe attacks</li><li>	Primary endpoint was percentage of patients pain free at 2 hours and percentage of patients free of their most bothersome symptom at 2 hours
<ul><li>	In both studies, 28% to 38% of patients were pain free at 2 hours</li><li>	About two-thirds had relief of headache in 2 hours</li><li>	More than 40% had relief of the most bothersome symptom</li></ul></li><li>	Both studies showed that all 3 doses tested -- 50, 100, 200 mg -- were all highly statistically superior to placebo</li><li>	No serious safety signals 
<ul><li>	Dizziness the most common adverse event, reported in about 16% to 18% of patients</li></ul></li><li>	Lasmiditan, if approved, will provide an option for patients for whom triptans are contraindicated
<ul><li>	Option also for patients for whom triptans were not effective or were not tolerated</li></ul></li></ul></sec_txt><sec_alt_txt>Slide 3.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_5/Slide4.png</sec_img><sec_label>Slide 4.</sec_label><sec_caption/><sec_txt><h3> Rimegepant for Acute Treatment of Migraine: Phase 3 Study Results<sup type="ref">[13,14]</sup></h3><ul><li>	Studies looked at efficacy of 2 calcitonin gene-related peptide (CGRP)-receptor antagonists
<ul><li>	CGRP is an important neuropeptide in the pathogenesis of migraine</li></ul></li><li>	CGRP receptor antagonists rimegepant and ubrogepant evaluated in large randomized placebo-controlled studies
<ul><li>	Two studies each, or 4 studies in total</li></ul></li><li>	Both CGRP receptor antagonists were shown to be superior to placebo
<ul><li>	Pain-free rates of about 20% for both molecules</li><li>	About two-thirds of patients achieved relief of headache at 2 hours</li></ul></li></ul></sec_txt><sec_alt_txt>Slide 4.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_5/Slide5.png</sec_img><sec_label>Slide 5.</sec_label><sec_caption/><sec_txt><h3>Ubrogepant for Acute Treatment of Migraine: Phase 3 Study Results<sup type="ref">[15,16]</sup></h3><ul><li>	Percentage of patients able to return to normal function exceeded 40% in studies evaluating these CGRP receptor antagonists</li><li>	Like lasmiditan, CGRP receptor antagonists do not constrict blood vessels
<ul><li>	Should have no contraindication for patients with established cardiovascular disease or significant risk factors for cardiovascular disease</li></ul></li><li>	No serious safety signals seen with either drugs in any of the 4 studies
<ul><li>	No serious side effects</li><li>	Side effect profile for both compounds look very similar and comparable to placebo</li></ul></li></ul></sec_txt><sec_alt_txt>Slide 5.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_5/Slide6.png</sec_img><sec_label>Slide 6.</sec_label><sec_caption/><sec_txt><h3> CGRP-Targeting mAbs for Migraine Prevention<sup type="ref">[6,17-26]</sup></h3><ul><li>	Erenumab, a CGRP-targeting mAb, has been approved by the US Food and Drug Administration (FDA) for prevention of migraine</li><li>	Two drugs are under FDA review right now and a third, an intravenous formulation, is completing phase 3 trials</li><li>	All of these mAbs are effective for the preventive treatment of episodic migraine and chronic migraine</li></ul></sec_txt><sec_alt_txt>Slide 6.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_5/Slide7.png</sec_img><sec_label>Slide 7.</sec_label><sec_caption/><sec_txt><h3> Early Rapid Onset of CGRP-Targeting mAbs<sup type="ref">[27-29]</sup></h3><ul><li>	Effective in reducing the frequency of migraine</li><li>	Rapid onset of effect, within about a day or a week
<ul><li>	Unprecedented, for preventive treatments for migraine</li></ul></li></ul></sec_txt><sec_alt_txt>Slide 7.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_5/Slide8.png</sec_img><sec_label>Slide 8.</sec_label><sec_caption/><sec_txt><h3> Benefit of CGRP-Targeting mAbs in Difficult-to-Treat Populations<sup type="ref">[30-35]</sup></h3><ul><li>	Effective in patients who were otherwise medically or treatment resistant</li><li>	Effective in patients who have failed multiple prophylactic medications</li><li>	Effective in patients with medication overuse headache, independent of withdrawal from acute analgesics</li><li>	Unique attributes that go far above and beyond just their efficacy in preventing or reducing the frequency of migraine</li></ul></sec_txt><sec_alt_txt>Slide 8.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_5/Slide9.png</sec_img><sec_label>Slide 9.</sec_label><sec_caption/><sec_txt><h3> Conclusions</h3></sec_txt><sec_alt_txt>Slide 9.</sec_alt_txt><qna_form/></slide_grp></subsec_element></sec_element><pg_footnotes/></toc_element><toc_element><toc_label/><toc_type>Default</toc_type><sec_element><sec_header><p> Emerging Approaches for Preventive Therapy of Chronic Migraine</p></sec_header><subsec_element><subsec_header/><slide_intro><div class="app-loading"><div class="webcomp-player" data-config="en/pi/editorial/studio/configs/2019/education/900319/900319_6.json" data-playertype="edu" id="cme-video-player">
                &#160;
            </div></div></slide_intro><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_6/Slide1.png</sec_img><sec_label>Slide 1.</sec_label><sec_caption/><sec_txt><h3> Emerging Approaches for Preventive Therapy of CM</h3></sec_txt><sec_alt_txt>Slide 1.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_6/Slide2.png</sec_img><sec_label>Slide 2.</sec_label><sec_caption/><sec_txt><h3> CM: Features and Challenges<sup type="ref">[6,36,37]</sup></h3><ul><li>	CM and EM are clinically, functionally, and anatomically differentiated
<ul><li>	Evidence suggests they may be separate conditions</li></ul></li><li>	Patients with CM usually have more comorbid conditions and more frequent medication overuse
<ul><li>	Complicates clinical management of CM</li></ul></li><li>	Estimated rate of reversion from CM to EM is relatively low
<ul><li>	Studies report remission rates of about 15% to 26%</li></ul></li><li>	Several mAbs targeting CGRP are in development
<ul><li>	The first was recently approved for migraine prevention</li></ul></li></ul></sec_txt><sec_alt_txt>Slide 2.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_6/Slide3.png</sec_img><sec_label>Slide 3.</sec_label><sec_caption/><sec_txt><h3> Fremanezumab for Prevention of CM: HALO-CM<sup type="ref">[22]</sup></h3><ul><li>	Study looked at reversion of patients with CM to EM with fremanezumab treatment</li><li>	Fremanezumab is a CGRP mAb that can be given as a monthly or quarterly injection for prevention of migraine
<ul><li>	In clinical trials, shown to significantly reduce frequency of migraine and headache without serious treatment-related adverse events</li></ul></li><li>	Phase 3 HALO-CM study
<ul><li>	Patients aged 18 to 70 years with history of migraine for at least 12 months and who met International Classification of Headache Disorders (ICHD)-3 criteria for CM</li><li>	Randomly assigned to fremanezumab given monthly or quarterly or placebo</li><li>	Patients kept a daily diary and completed other questionnaires at regular intervals</li></ul></li><li>	Primary endpoint was mean change in the monthly average number of headache days of at least moderate severity at 12 weeks vs baseline
<ul><li>	Secondary endpoints included safety and tolerability measures</li></ul></li><li>	Study met all of its endpoints</li></ul></sec_txt><sec_alt_txt>Slide 3.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_6/Slide4.png</sec_img><sec_label>Slide 4.</sec_label><sec_caption/><sec_txt><h3> Reversion From CM to EM With Fremanezumab in HALO-CM<sup type="ref">[38]</sup></h3><ul><li>	Post hoc analysis of HALO-CM data looked at proportion of patients who reverted from CM to EM
<ul><li>	Met primary outcome</li></ul></li><li>	Fremanezumab demonstrated efficacy as a preventive treatment for CM
<ul><li>	Decrease in mean MHD over the treatment period</li></ul></li><li>	Demonstrated potential benefit for reversion from CM to EM</li></ul></sec_txt><sec_alt_txt>Slide 4.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_6/Slide5.png</sec_img><sec_label>Slide 5.</sec_label><sec_caption/><sec_txt><h3> Eptinezumab for Prevention of CM: PROMISE-2<sup type="ref">[21]</sup></h3><ul><li>	PROMISE-2 study of the CGRP-targeting mAb eptinezumab as a preventive therapy for CM
<ul><li>	Randomly assigned to a single quarterly infusion of 100 mg or 300 mg dose of eptinezumab or placebo</li><li>	Enrolled more than 1000 patients who had approximately 16 monthly migraine days at baseline</li></ul></li><li>	Subjects in both eptinezumab groups had a greater reduction in monthly migraine days vs placebo</li><li>	Study also met secondary endpoints
<ul><li>	More than half of subjects achieved &gt;50% reduction in MMD from weeks 1 to 12 and at monthly intervals</li><li>	Significantly higher proportion of patients on eptinezumab achieved 100% reduction in monthly migraine days vs placebo</li></ul></li></ul></sec_txt><sec_alt_txt>Slide 5.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_6/Slide6.png</sec_img><sec_label>Slide 6.</sec_label><sec_caption/><sec_txt><h3> Conclusions</h3></sec_txt><sec_alt_txt>Slide 6.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/900/319/900319_6/Slide7.png</sec_img><sec_label>Slide 7.</sec_label><sec_caption/><sec_txt><h3> Thank You</h3></sec_txt><sec_alt_txt>Slide 7.</sec_alt_txt><qna_form/></slide_grp><slide_grp><sec_img/><sec_label/><sec_caption/><sec_txt><em>This content has been condensed for improved clarity.</em></sec_txt><sec_alt_txt/><qna_form/></slide_grp></subsec_element><subsec_element><subsec_header><p>Educational Impact Challenge</p></subsec_header><slide_intro><p>What did you learn from this activity? Please click on the "Next" button to proceed to a brief survey to see how your knowledge improved after the education. You can also see how your answers compare with those of your peers.</p></slide_intro></subsec_element></sec_element><pg_footnotes/></toc_element><toc_element><toc_label/><toc_type>Default</toc_type><sec_element><sec_header><p>Educational Impact Challenge</p></sec_header><subsec_element><subsec_header/><slide_intro/><slide_grp><sec_img/><sec_label/><sec_caption/><sec_txt/><sec_alt_txt/><qna_form>4</qna_form></slide_grp></subsec_element></sec_element><pg_footnotes/></toc_element><toc_element><toc_label/><toc_type>Default</toc_type><sec_element><sec_header/><subsec_element><subsec_header/><slide_intro/><slide_grp><sec_img/><sec_label/><sec_caption/><sec_txt/><sec_alt_txt/><qna_form/></slide_grp></subsec_element></sec_element><pg_footnotes/></toc_element><toc_element><toc_label><p>Abbreviations</p></toc_label><toc_type>Sidebar</toc_type><sec_element><sec_header><p>Abbreviations</p></sec_header><subsec_element><subsec_header/><slide_intro><p>5-HT = 5-hydroxytryptamine<br/>CaMEO = Chronic Migraine Epidemiology and Outcomes <br/>CGRP = calcitonin gene-related peptide<br/>CM = chronic migraine<br/>EM = episodic migraine<br/>HDM = headache days per month<br/>HIT-6 = Headache Impact Test<br/>ICHD = International Classification of Headache Disorders<br/>mAb = monoclonal antibody<br/>MBS = most bothersome symptom<br/>MIDAS = Migraine Disability Assessment questionnaire<br/>mITT = modified intent to treat<br/>MMD = monthly migraine days<br/>MPFID = Migraine Physical Function Impact Diary<br/>MSQ = Migraine Specific Quality of life questionnaire<br/>OR = odds ratio<br/>Psych = psychiatric<br/>PTSD = posttraumatic stress disorder<br/>Resp = respiratory<br/>SR = self-reported<br/>SR-PD = self-reported physician diagnosis<br/>TEAE = treatment-emergent adverse event</p></slide_intro></subsec_element></sec_element><pg_footnotes/></toc_element><toc_element><toc_label/><toc_type>References</toc_type><sec_element><sec_header/><subsec_element><subsec_header/><slide_intro><ol><li>Adams AM, Serrano D, Buse DC, et al. The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. <em>Cephalalgia. </em>2015;35:563-578.</li><li>Lipton RB, Fanning KM, Reed ML, et al. Self perceptions of what life would be like without migraine in major life domains: results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Poster presented at: 60th Annual Scientific Meeting of the American Headache Society; June 28 - July 1, 2018; San Francisco, California. Poster PF13.</li><li>Adams AM, Buse DC, Fanning KM, et al. Perceived effect of migraine on career and finances: results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Poster presented at: 60th Annual Scientific Meeting of the American Headache Society; June 28 - July 1, 2018; San Francisco, California. Poster PF01.</li><li>Buse DC, Dumas PK, Murray S, et al. Life with migraine, effect on relationships: results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Presented at: 60th Annual Scientific Meeting of the American Headache Society; June 28 - July 1, 2018; San Francisco, California. Presentation OR06.</li><li>Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). <em>Headache. </em>2013;53:644-655.</li><li>Dodick DW. Migraine. <em>Lancet. </em>2018;391:1315-1330.</li><li>Mannix S, Skalicky A, Buse DC, et al. Measuring the impact of migraine for evaluating outcomes of preventive treatments for migraine headaches. <em>Health Qual Life Outcomes. </em>2016;14:143.</li><li>Kawata AK, Hsieh R, Bender R, et al. Psychometric evaluation of a novel instrument assessing the impact of migraine on physical functioning: the Migraine Physical Function Impact Diary. <em>Headache. </em>2017;57:1385-1398.</li><li>Lipton RB, Buse DC, Dodick DW, et al. Measuring the impact of migraine on days before, during, and after a migraine using the Migraine Physical Function Impact Diary (MPFID). Poster presented at: 60th Annual Scientific Meeting of the American Headache Society; June 28 - July 1, 2018; San Francisco, California. Poster PF120LB.</li><li>Lipton RB, Fanning KM, Buse DC, et al. Identifying natural subgroups of migraine based on profiles of comorbidities and concomitant conditions: results of the Chronic Migraine Epidemiology and Outcomes study. Presented at: 60th Annual Scientific Meeting of the American Headache Society; June 28 - July 1, 2018; San Francisco, California. Presentation OR17.</li><li>Reuter U, Israel H, Neeb L. The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine. <em>Ther Adv Neurol Disord. </em>2015;8:46-54.</li><li>Wietecha L, Kuca B, Asafu-Adjei J, et al. Phase 3 studies (SAMURAI, SPARTAN) of lasmiditan compared to placebo for acute treatment of migraine. Presented at: 60th Annual Scientific Meeting of the American Headache Society; June 28 - July 1, 2018; San Francisco, California. Presentation IOR02.</li><li>Lipton RB, Coric V, Stock EG, et al. Efficacy, safety, and tolerability of rimegepant 75 mg, an oral CGRP receptor antagonist, for the acute treatment of migraine: results from a phase 3, double-blind, randomized, placebo-controlled trial, Study 302. . Presented at: 60th Annual Scientific Meeting of the American Headache Society; June 28 - July 1, 2018; San Francisco, California. Presentation IOR02LB.</li><li>Lipton RB, et al. Efficacy, safety, and tolerability of rimegepant 75 mg, an oral CGRP receptor antagonist, for the acute treatment of migraine: results from a double-blind, randomized, placebo-controlled trial, Study 301. Poster presented at: 60th Annual Scientific Meeting of the American Headache Society; June 28 - July 1, 2018; San Francisco, California. Poster PS123LB.</li><li>Dodick DW, et al. Ubrogepant for the acute treatment of migraine: efficacy, safety, tolerability, and functional impact outcomes from a single attack phase III study, ACHIEVE I. Presented at: 60th Annual Scientific Meeting of the American Headache Society; June 28 - July 1, 2018; San Francisco, California. Presentation IOR01LB.</li><li>Lipton RB, Dodick DW, Ailani J, et al. Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: results from a single attack, phase III study, ACHIEVE II. Poster presented at: 60th Annual Scientific Meeting of the American Headache Society; June 28 - July 1, 2018; San Francisco, California. Poster PS111LB.</li><li>Goadsby PJ, Reuter U, Hallstrom Y, et al. A controlled trial of erenumab for episodic migraine. <em>N Engl J Med. </em>2017;377:2123-2132.</li><li>Dodick DW, Ashina M, Brandes JL, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. <em>Cephalalgia. </em>2018;38:1026-1037.</li><li>Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. <em>Lancet Neurol. </em>2017;16:425-434.</li><li>Silberstein S, Kudrow D, Saper J, et al. Eptinezumab results for the prevention of episodic migraine over 1 year in the PROMISE-1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy–1) trial. Poster presented at: 60th Annual Scientific Meeting of the American Headache Society; June 28 - July 1, 2018; San Francisco, California. Poster PF108LB.</li><li>Lipton RB, Goadsby PJ, Azimova J, et al. Eptinezumab for prevention of chronic migraine: results of 2 quarterly intravenous infusions in the phase 3 PROMISE-2 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy–2) trial. Poster presented at: 60th Annual Scientific Meeting of the American Headache Society; June 28 - July 1, 2018; San Francisco, California. Poster PF110LB.</li><li>Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. <em>N Engl J Med. </em>2017;377:2113-2122.</li><li>Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. <em>JAMA Neurol. </em>2018. doi: 10.1001/jamaneurol.2018.1212. [Epub ahead of print]</li><li>Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. <em>Cephalalgia. </em>2018. doi: 10.1177/0333102418779543. [Epub ahead of print]</li><li>Detke HC, Wang S, Skljarevski V, et al. A phase 3 placebo-controlled study of galcanezumab in patients with chronic migraine: results from the 3-month double-blind treatment phase of the REGAIN study. Poster presented at: 59th Annual Scientific Meeting of the American Headache Society; June 8-11, 2017; Boston, Massachusetts. Poster PS89LB.</li><li>Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. <em>JAMA. </em>2018;319:1999-2008.</li><li>Kudrow D, Diamond M, McGill L, et al. Eptinezumab achieved meaningful reductions in migraine activity as early as day 1: PROMISE-2 (PRevention of Migraine via Intravenous Eptinezumab Safety and Efficacy-2) phase 3 trial in chronic migraine. Presented at: 60th Annual Scientific Meeting of the American Headache Society; June 28 - July 1, 2018; San Francisco, California. Presentation IOR04.</li><li>Yeung PP, Aycardi E, Bigal ME, et al. Early onset of action with fremanezumab versus placebo for the preventive treatment of episodic migraine. Poster presented at: 60th Annual Scientific Meeting of the American Headache Society; June 28 - July 1, 2018; San Francisco, California. Poster PF43.</li><li>Aurora S, Detke H, Millen B. Rapid onset of effect of galcanezumab for the prevention of episodic migraine: post-hoc analyses of two phase 3 studies. Presented at: 60th Annual Scientific Meeting of the American Headache Society; June 28 - July 1, 2018; San Francisco, California. Presentation IOR05.</li><li>Ailani J, Pearlman E, Zhang Q, et al. Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine. Poster presented at: 60th Annual Scientific Meeting of the American Headache Society; June 28 - July 1, 2018; San Francisco, California. Poster PS106LB.</li><li>Ruff D, Pearlman EM, Govindan S, et al. Efficacy of galcanezumab in patients who failed to respond to preventives previously: results from EVOLVE-1, EVOLVE-2, and REGAIN studies. Poster presented at: 60th Annual Scientific Meeting of the American Headache Society; June 28 - July 1, 2018; San Francisco, California. Poster PS29.</li><li>Pascual J, Buse DC, Starling AJ, et al. Effect of erenumab on patient-reported outcomes in episodic migraine patients with prior prophylactic treatment failure: Results from a post-hoc analysis of the STRIVE study. Poster presented at: 60th Annual Scientific Meeting of the American Headache Society; June 28 - July 1, 2018; San Francisco, California. Poster PS49.</li><li>Ashina M, Tepper SJ, Brandes J, et al. Long-term efficacy of erenumab in subjects with chronic migraine who failed prior prophylactic treatment. Poster presented at: 60th Annual Scientific Meeting of the American Headache Society; June 28 - July 1, 2018; San Francisco, California. Poster PF106LB.</li><li>Brandes JL, Sakai F, Yeung PP, et al. Impact of fremanezumab on the number of days with use of acute headache medications in episodic migraine. Poster presented at: 60th Annual Scientific Meeting of the American Headache Society; June 28 - July 1, 2018; San Francisco, California. Poster PF44.</li><li>Silberstein SD, Ashina S, Katsarava Z, et al. The impact of fremanezumab on medication overuse in patients with chronic migraine. Presented at: 60th Annual Scientific Meeting of the American Headache Society; June 28 - July 1, 2018; San Francisco, California. Presentation IOR07.</li><li>Manack A, Buse DC, Serrano D, et al. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. <em>Neurology. </em>2011;76:711-718.</li><li>Ferrari A, Leone S, Vergoni AV, et al. Similarities and differences between chronic migraine and episodic migraine. <em>Headache. </em>2007;47:65-72.</li><li>Halker Singh RB, Cohen J, Bibeau K, et al. Reversion of patients with chronic migraine to an episodic migraine classification with fremanezumab treatment. Presented at: 60th Annual Scientific Meeting of the American Headache Society; June 28 - July 1, 2018; San Francisco, California. Presentation OR15.</li></ol></slide_intro></subsec_element></sec_element><pg_footnotes/></toc_element><back_label>Back Matter</back_label><ref_grp><ref_item/></ref_grp><cpyrt_holder><p>Medscape, LLC</p></cpyrt_holder><cpyrt_ovrd/><disclmr_ovrd/><bkmtr_front><p><strong>Disclaimer</strong></p><p>The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.</p></bkmtr_front><bkmtr_glossary/><bkmtr_ack/><bkmtr_discl/><bkmtr_funding/><bkmtr_reprnt_addr/><bkmtr_abbr_notes/><bkmtr_last/><img_ttl_bkgrd/><img_publ_logo/></prof_article_slide_presentation>